Newsroom
Strive to Deliver Breakthroughs
-
October 20, 2022
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States
Cambridge, MA, Rotterdam, NL, Suzhou, CN— October 20, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successful...
View more -
October 13, 2022
Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
Cambridge, MA, Rotterdam, NL, Suzhou, CN — October 13, 2022 Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceuti...
View more -
October 10, 2022
Harbour BioMed Enters into Agreement with CSPC Pharmaceutical Group Limited for Batoclimab (HBM9161) in Greater China
Cambridge, MA, Rotterdam, NL, Suzhou, CN - October 10, 2022 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical com...
View more -
September 27, 2022
Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 27, 2022 Harbour BioMed (“HBM”, HKEX: 02142) today announces that it has com...
View more -
August 31, 2022
Harbour BioMed Announces 2022 Interim Results: Revenue Grows by 1155% with Landmark Acceleration in Core Innovation Strength and Platforms Value
CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - August 31, 2022 Harbour BioMed (“HBM”, or the "Company”; HK...
View more -
August 09, 2022
Harbour BioMed to Announce 2022 Interim Results on August 31, 2022
Cambridge, MA, Rotterdam, NL, Suzhou, CN – Aug 9, 2022 Harbour BioMed (the “Company”, HKEX: 02142) announced that it will repor...
View more -
August 08, 2022
PNAS Published Preclinical Results of Harbour BioMed’s Next-Generation Fully Human Heavy-chain Antibody Porustobart
Cambridge, MA, Rotterdam, NL, Suzhou, CN— Aug 8, 2022 Harbour BioMed (the “Company”, HKEX: 02142) announced that the preclinica...
View more -
June 27, 2022
Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration
Cambridge, MA, Rotterdam, NL, Suzhou, CN — June 27, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that the U.S. Food and Dr...
View more -
June 08, 2022
Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody
Cambridge, MA, Rotterdam, NL, Suzhou, CN — June 8, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that China National Medica...
View more -
June 01, 2022
Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism
Cambridge, MA, Rotterdam, NL, Suzhou, CN — Jun 1, 2022 Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical ...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1